Cellectis (NASDAQ:CLLS) Upgraded to Hold by ValuEngine

ValuEngine upgraded shares of Cellectis (NASDAQ:CLLS) from a sell rating to a hold rating in a research report sent to investors on Thursday, ValuEngine reports.

Several other equities analysts have also recently issued reports on CLLS. Citigroup reiterated a neutral rating and set a $22.00 target price on shares of Cellectis in a research report on Friday, May 24th. Zacks Investment Research upgraded Cellectis from a hold rating to a buy rating and set a $17.00 target price on the stock in a research report on Thursday, July 18th. Finally, BidaskClub cut Cellectis from a hold rating to a sell rating in a research report on Friday, July 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Cellectis has an average rating of Hold and an average price target of $31.60.

NASDAQ CLLS traded down $1.00 on Thursday, hitting $13.74. 167,839 shares of the company’s stock were exchanged, compared to its average volume of 90,678. The company has a current ratio of 9.77, a quick ratio of 9.74 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $15.43. Cellectis has a fifty-two week low of $13.60 and a fifty-two week high of $29.97. The stock has a market cap of $605.36 million, a price-to-earnings ratio of -7.12 and a beta of 1.72.

Cellectis (NASDAQ:CLLS) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.27. Cellectis had a negative return on equity of 14.85% and a negative net margin of 401.24%. The company had revenue of $3.43 million for the quarter, compared to analysts’ expectations of $3.70 million. As a group, equities analysts expect that Cellectis will post -2.32 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. acquired a new stake in shares of Cellectis in the 1st quarter worth approximately $96,000. Aperio Group LLC acquired a new stake in shares of Cellectis in the 2nd quarter worth approximately $147,000. Two Sigma Investments LP acquired a new stake in shares of Cellectis in the 4th quarter worth approximately $180,000. Squarepoint Ops LLC grew its holdings in shares of Cellectis by 28.3% in the 4th quarter. Squarepoint Ops LLC now owns 16,455 shares of the biotechnology company’s stock worth $274,000 after acquiring an additional 3,626 shares during the period. Finally, Northern Trust Corp acquired a new stake in shares of Cellectis in the 4th quarter worth approximately $301,000. Institutional investors and hedge funds own 30.58% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Featured Story: What is a growth and income fund?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.